Highlights Virax Biolabs Group Limited

Equities

VRAX

KYG9495L1251

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 15/05/2026 BST			5-day change	1st Jan Change
0.1535 ^USD	+9.64%		-10.23%	-55.61%

03-18	Virax Biolabs Group Limited Approves Fourth Amended and Restated Memorandum and Articles of Association	CI
12-03	Virax Biolabs Group Limited announced that it has received $4.99875 million in funding	CI

Highlights

12-02	Virax Biolabs Group Limited Reports Earnings Results for the Half Year Ended September 30, 2025	CI
11-03	Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive Fda Feedback for Viraximmune?? Study Evaluating T Cell Dysfunction in Post-Acute Infection Syndromes	CI
26/08/25	Virax Biolabs to Collaborate With Emory University on Long COVID Clinical Studies	MT
26/08/25	Virax Biolabs partners with Emory University on ViraxImmune(TM) clinical studies	RE
26/08/25	Virax Biolabs Group Limited Partners with Emory University on ViraxImmune Clinical Studies	CI
02/07/25	Virax Biolabs Group Limited Reports Earnings Results for the Full Year Ended March 31, 2025	CI
18/03/25	Virax Biolabs Group Limited Enrolls First Patients in Clinical Study Assessing T Cell Dysfunction in Post-Acute Infection Syndromes	CI
13/03/25	Virax Biolabs Group Limited Presents Data on T-Cell Dysfunction in Post-Acute Infection Syndromes at the 19th World Immune Regulation Meeting	CI
13/01/25	Cosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC Countries	CI
17/12/24	Virax Biolabs Group Limited Announces New Distribution Agreements	CI
17/12/24	Virax Biolabs Initiates UK Clinical Study for ViraxImmune? Platform to Detect T-Cell Dysfunction in Post-Acute Infectious Syndrome Patients	CI
20/11/24	Virax Biolabs Group Limited Reports Earnings Results for the Half Year Ended September 30, 2024	CI
23/10/24	Virax Biolabs Group Limited Announces Distribution Agreement with Europa Biosite to Commercialize ImmuneSelect in the United Kingdom and Ireland	CI
16/09/24	Virax Biolabs Extends Exclusive Distribution Deal for Mpox Virus Test Kits; Shares Rise Pre-Bell	MT
16/09/24	Cosmos Health Secures Exclusivity Agreement with Virax Biolabs to Distribute mpox PCR Kits Across the GCC, Including the UAE, Saudi Arabia, Bahrain, Kuwait, Oman, and Qatar	CI
28/08/24	Top Midday Gainers	MT
28/08/24	Virax Biolabs to Distribute Mpox Detection Kits Across Europe, GCC	MT
28/08/24	Virax Biolabs Announces Distribution Agreement to Commercialize Mpox (formerly Monkeypox) Virus RT-PCR Detection Kits in Europe and the Middle East	CI
23/08/24	Virax Biolabs Closes $5 Million Direct Offering of Shares	MT
22/08/24	Virax Biolabs Group Signs Deal for $5 Million Share Offering	MT
20/08/24	Virax Biolabs Group Limited Reports Earnings Results for the Full Year Ended March 31, 2024	CI
06/06/24	Top Premarket Gainers	MT
25/04/24	Virax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024	CI
12/01/24	Virax Biolabs Group Limited Reports Earnings Results for the Half Year Ended September 30, 2023	CI
21/12/23	Virax Biolabs Group Limited Forges Strategic Research Collaboration with University of Manchester and Northern Care Alliance Foundation Trust to Enhance Understanding of Immune Responses in COVID Patients	CI